Document Detail

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
MedLine Citation:
PMID:  12963476     Owner:  NLM     Status:  MEDLINE    
IN CONCLUSION: (i) FK228 showed a suppressive effect on the expression of angiogenesis factors, such as VEGF and bFGF, in PC-3 xenograft but not in ACHN xenograft, which suggests that the effect on the expression of angiogenesis factors is important for the antitumor efficacy of FK228; (ii) FK228 caused histone acetylation of the VEGF promoter regions, which may contribute to the suppression of VEGF gene expression.
Yuka Sasakawa; Yoshinori Naoe; Takahisa Noto; Takeshi Inoue; Tatsuya Sasakawa; Masahiko Matsuo; Toshitaka Manda; Seitaro Mutoh
Related Documents :
17372666 - Effect of low shear stress on permeability and occludin expression in porcine artery en...
15010886 - Expression of vegf and brain specific angiogenesis inhibitor-1 in glioblastoma: prognos...
16319286 - Sphingosine-1-phosphate receptor expression and signaling correlate with uterine prosta...
18320356 - Promoter sequence variants of light are associated with female vascular dementia.
1350056 - Inhibition of tyrosine aminotransferase gene expression by retinoic acid.
21351246 - Development of lamprey mucocartilage and its dorsal-ventral patterning by endothelin si...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Biochemical pharmacology     Volume:  66     ISSN:  0006-2952     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-09-09     Completed Date:  2003-10-16     Revised Date:  2014-07-28    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  897-906     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetylation / drug effects
Angiogenesis Inducing Agents
Antibiotics, Antineoplastic / pharmacology*,  therapeutic use
Chromatin / metabolism
DNA-Binding Proteins / metabolism
Disease Models, Animal
Endothelial Growth Factors / metabolism*
Enzyme Inhibitors / pharmacology,  therapeutic use
Fibroblast Growth Factor 2 / metabolism*
Gene Expression / drug effects
Histone Deacetylase Inhibitors*
Hypoxia-Inducible Factor 1
Hypoxia-Inducible Factor 1, alpha Subunit
Intercellular Signaling Peptides and Proteins / metabolism*
Lymphokines / metabolism*
Mice, Inbred BALB C
Neoplasm Transplantation
Nuclear Proteins / metabolism
Peptides, Cyclic / pharmacology*,  therapeutic use
Promoter Regions, Genetic
RNA, Messenger / drug effects,  metabolism
Transcription Factors*
Tumor Cells, Cultured
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Xenograft Model Antitumor Assays
Reg. No./Substance:
0/Angiogenesis Inducing Agents; 0/Antibiotics, Antineoplastic; 0/Chromatin; 0/DNA-Binding Proteins; 0/Depsipeptides; 0/Endothelial Growth Factors; 0/Enzyme Inhibitors; 0/Hif1a protein, mouse; 0/Histone Deacetylase Inhibitors; 0/Hypoxia-Inducible Factor 1; 0/Hypoxia-Inducible Factor 1, alpha Subunit; 0/Intercellular Signaling Peptides and Proteins; 0/Lymphokines; 0/Nuclear Proteins; 0/Peptides, Cyclic; 0/RNA, Messenger; 0/Transcription Factors; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors; 103107-01-3/Fibroblast Growth Factor 2; 128517-07-7/romidepsin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3.
Next Document:  Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid--extensive ...